Boostrix, Adacel Seek Approval Based On Studies Comparing Infants And Adolescents
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA vaccine advisory committee will meet March 15 to review the Tdap boosters from GlaxoSmithKline and Sanofi Pasteur. The products are intended to address the rising incidence of pertussis. Applications rely on trial design recommended by the committee in 1997.